The Role of Fiber in the Treatment of Functional Gastrointestinal Disorders in Children

Cara Hannah Axelrod * and Miguel Saps

Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Miami Miller School of Medicine, Miami, FL 33136, USA; msaps@med.miami.edu
* Correspondence: cxa630@med.miami.edu; Tel.: +1-(305)-243-3166

Received: 8 October 2018; Accepted: 27 October 2018; Published: 3 November 2018

Abstract: We reviewed the available evidence on the role of fiber in the treatment of Functional Constipation (FC) and Irritable Bowel Syndrome (IBS) in children. The vast majority of toddlers and preschoolers do not consume enough fiber. Two of the most common reasons for consultation to a pediatric gastroenterology practice include FC and IBS. The North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines state that the evidence does not support the use of fiber supplements in the treatment of FC in children, and the Rome IV criteria do not recommend an increase in fiber consumption, in children with IBS. Despite this, in general practice, it is commonly recommended that children who experience constipation and IBS to increase their fiber intake. We conducted a systematic review of the available evidence on the role of fiber in the treatment of FC and IBS in children. Thirteen full-text articles with a total of seven hundred and twenty-three pediatric participants were included in this review. Three clinical trials found positive effects of dietary fiber for the management of IBS. Nine out of ten trials found fiber to be either more effective than placebo, or just as effective as laxative treatment. Most studies on the use of fiber for the treatment of FC and IBS have shown its benefit. However, due to the heterogeneity in study design, length of treatment, outcome measures, and amount and type of fiber, we were unable to make a definitive recommendation supporting the use of fiber for the treatment of FC and IBS in children.

Keywords: functional constipation; irritable bowel syndrome; abdominal pain; fiber; children

1. Introduction

The Rome IV criteria classifies functional gastrointestinal disorders (FGIDs) in the disorders of nausea and vomiting, disorders of defecation (functional constipation (FC) and functional non-retentive fecal incontinence) and functional abdominal pain disorders (irritable bowel syndrome (IBS), functional dyspepsia, abdominal migraine, and functional abdominal pain not otherwise specified) [1].

FGIDs in children is a public health problem. Approximately, one in sixteen school-age children are diagnosed with IBS [2], most of them have IBS with constipation (IBS-C) [3]. FC alone has a reported prevalence, ranging between 0.7% and 29.6%, with a world-pooled prevalence of 9.5% [4]. Hereditary or environmental factors may play a role in the development of these conditions. FGIDs are associated with anxiety and lower health-related quality of life in physical, social, emotional, and school functioning [5]. As a result, IBS and FC are among the most common reasons for consultation with pediatric gastroenterology [6].

The treatment of FGIDs includes changes in lifestyle, diet, and medications, when needed. Some of the most commonly recommended dietary changes for FC are to increase the ingestion of fluids and fiber. Most of the water in the intestines is not ingested but results from intestinal secretions. Water is reabsorbed in the small and large intestine [7] with a very small percentage of it present in the
Heartburn, peptic ulcer disease, and gastritis are associated with acid secretion. While the role of parietal cells is well understood, the impact of hydrogen carbonate-producing cells remains uncertain. These cells give rise to hydrogen carbonate, which neutralizes the acidic environment in the stomach. While the role of hydrogen carbonate-producing cells is not as well understood, they are believed to play a role in maintaining the acid balance in the stomach.


diagnosis of functional gastrointestinal disorders (FGIDs). FGIDs are characterized by symptoms that are not caused by a structural or biochemical abnormality. The most common FGIDs include functional dyspepsia, irritable bowel syndrome (IBS), and functional constipation (FC).

Fibers are categorized as soluble or insoluble. Soluble fibers are fermented in the colon whereas insoluble fibers are subject to limited fermentation. Soluble fiber absorbs water, forming a gel after digestion. The added water is thought to make the stool softer and easier to pass. Common sources of soluble fiber include oatmeal, barley, beans, lentils, and peas. Insoluble fibers have a bulking action and can only be fermented in the colon producing gas and worsening the IBS symptoms. Insoluble fibers do not get broken down completely in the body, and help food pass more quickly through the intestines. Wheat bran, whole grains, and some vegetables, all contain insoluble fiber.

A large number of soluble and insoluble fiber sources that have been studied for different ailments include, Gum Acacia, Alginate, Apple Fiber, Bamboo Fiber, Carboxymethyl Cellulose, Corn Hull Fiber, Cottonseed Fiber, Galactooligosaccharides (GOS), Inulin/Oligofructose/Synthetic Short-Chain Fructooligosaccharides, Karaya Gum, Oat Hull (Insoluble Oat) Fiber, pea fiber, Polydextrose, Potato Fibers, Pullulan, Rice Bran Fiber, High Amylose Corn/Maize Starch (Resistant Starch 2), Retrograded Corn Starch (Resistant Starch 3), Resistant Wheat and Maize Starch (Resistant Starch 4), Soluble Corn Fiber, Soy Fiber, Sugar Beet Fiber, Sugar Cane Fiber, Wheat Fiber, Xanthan Gum, and Xylooligosaccharides (XOS). Only few of them have been studied for the management of FGIDs.

The outcomes of treatment of FC and IBS are suboptimal. One in four children with FC and IBS continue to experience symptoms through adulthood. Approximately 40% of children that consult for FC continue to require treatment after five years. Parents frequently do not follow all the recommendations provided. Only 37% of parents that consult pediatric gastroenterology for the treatment of FC comply with the recommendations for laxatives. This may result from the desire for natural treatments, fear of side effects or difficulty in following a plan that may be too complex and with multiple recommendations. Thus, to enhance adherence and treatment success, it is important to ensure that the recommendations given to the parents are simple and based on the best evidence.

We conducted a systematic review of the available evidence on the role of fiber, in the treatment of FC and IBS in children.

2. Materials and Methods

PubMed/Medline and Scopus were searched from initiation through 23 August, 2018. To find evidence for fiber therapy in children, basic search terms were inputted: “children”, “childhood”, “pediatrics”, “fiber”, “recurrent abdominal pain (RAP)”, “functional abdominal pain”, “constipation”, and “irritable bowel syndrome”. Randomized controlled trials and randomized crossover trials published in English, with more than fifteen subjects, were included. Only studies involving infants, children, and adolescents (0–21 years of age), with functional gastrointestinal complaints, were included in this review. Studies were included if patients were diagnosed with FC, IBS, RAP or functional abdominal pain. We excluded studies that followed children with organic cause of defecation disorders, such as Hirschsprung’s disease, cystic fibrosis, anorectal malformations, or hypothyroidism.
Studies that compared fiber with lactulose, polyethylene glycol, or placebo were included. Abstracts were screened for eligibility, and those that met the criteria were read in full.

3. Results

Three hundred and eleven studies were identified. One hundred and forty-eight were non-duplicates and considered eligible. One hundred and twenty-two studies were excluded for the following reasons: The investigated therapies were enteral feedings, probiotics, electrical stimulation, Swiss-ball therapy, biofeedback training, behavioral interventions, and lubricants/laxatives, or the full-text article was not in English. Twenty-six abstracts were screened for relevancy by two reviewers. A total of twenty articles were reviewed in full by the authors. Finally, thirteen full-text clinical trials with a total of seven hundred and twenty-three pediatric participants met the inclusion criteria and were included in this review. We performed a descriptive analysis on the studies. Figure 1 shows the results of our literature search.

Figure 1. Flow diagram of the available evidence on the role of fiber, in the treatment of functional constipation (FC) and Irritable Bowel Syndrome (IBS) in children.
3.1. Studies on Single Fiber Types

3.1.1. Corn Fiber

Corn fiber is an insoluble residual endosperm, left after grain processing [21]. Due to its ability to resist digestion in the small intestine, it passes into the large intestine where it is fermented [22]. Corn fiber has been shown to improve laxation, when added to processed foods and beverages, in healthy adults [23].

One early (1985) randomized control trial evaluated corn fiber in children with abdominal pain [24]. Feldman et al. found that supplementing the diet with corn fiber reduced abdominal discomfort [24]. In this study, fifty-two children received either a high fiber cookie or a placebo cookie for six weeks. Primary outcome measures were intensity and frequency of abdominal pain. Each fiber cookie contained 5 g of corn fiber and children were instructed to consume them twice daily. Pain was rated using a “Stomach Ache Diary” four times daily. Pain episodes were significantly less frequent in the corn fiber group than the placebo group. Side effects of gas and diarrhea were minimal in both groups (Table 1).
### Table 1. Clinical Trials on Dietary Fiber for the Management of Irritable Bowel Syndrome.

| Author                  | Year Published | Location | Type of Study                          | N            | Age (Years) | Fiber Type | Soluble or Insoluble | Primary Outcome                        | Secondary Outcome | Dose            | Length of Treatment | Results                        |
|-------------------------|----------------|----------|----------------------------------------|--------------|-------------|------------|----------------------|-----------------------------------------|-------------------|-----------------|-----------------------|---------------------------------|
| William Feldman et al.  | 1985           | Canada   | Randomized, double-blind, parallel trial | 52           | 5–15        | Corn fiber vs. placebo | Soluble                | 50% decrease in frequency of pain episodes | None listed                  | 10 g daily | 2 weeks               | *p* = 0.04                      |
| Robert Shulman et al.   | 2017           | USA      | Randomized, double-blind parallel trial | 84           | 7–18        | Psyllium vs. placebo   | Soluble                | Pain episodes, Pain severity, Percentage of normal stools | Changes in breath hydrogen/methane production, Gut permeability | 7–11 years: 6 g daily | 12–18 years: 12 g daily | 6 weeks, *p* = 0.03, *p* = 0.97, *p* = 0.32, Breath hydrogen: *p* = 0.11/ Breath methane: *p* = 0.51, Gut permeability: NS |
| Claudio Romano et al.   | 2013           | Italy    | Randomized, double-blind parallel trial | 60           | 8–16        | Partially hydrolyzed guar gum vs. placebo | Soluble                | Stool frequency, Intensity of clinical symptoms | Compliance               | 5 g daily             | 4 weeks               | Stool frequency: *p* = 0.025, Intensity: *p* > 0.05 |
3.1.2. Partially Hydrolyzed Guar gum (PHGG)

Guar gum is a gel-forming fiber from the seeds of Cyamopsis tetragonolobus (guar plant) [27]. PHGG results from the hydrolysis of guar gum; it differs from guar gum as it is non-gel forming. As a water-soluble fiber, PHGG can be easily added into supplements due to its low viscosity, and odorless and tasteless nature [28]. Research in adults has shown that PHGG accelerates the colonic transit time in patients with chronic constipation and improves the frequency of bowel movements [29]. However, when used in the treatment of FC, among hospitalized patients, 10 g of PHGG did not differ in effects, compared to a 30 g high fiber diet, in terms of defecation frequency, fecal consistency, or the need for laxative drug use [30]. Two randomized control studies have evaluated PHGG, in children with FGID, and found promising results [26,31].

Ustundag et al. found PHGG to be as effective as lactulose for constipation related abdominal pain and stool consistency and to have less side effects [31]. In this prospective controlled study, sixty-eight children were randomized to receive either PHGG or lactulose, for four weeks. Children in the PHGG group were given different doses, depending on age (4–6 years: 3 g/day; 6–12 years: 4 g/day; and 12–16 years: 5 g/day), and were instructed to increase their fluid intake. Children in the lactulose group were given 1 mL/kg/day but were not instructed to increase their fluid intake. Bowel diaries were kept by the patients or parents to collect data regarding stools. Sixty-one patients completed the study, and both stool frequency and consistency improved significantly. However, no statistical difference was noted between the groups. The only side effect documented was increased flatulence in the lactulose group. Thus, this study found that treatment with PHGG and lactulose were equally effective for improving stool consistency (Table 2).
Table 2. Clinical Trials on Dietary Fiber for the Management of Functional Constipation.

| Author                          | Year Published | Location   | Type of Study                     | N    | Age (Years) | Fiber Type                           | Water Soluble or Insoluble | Primary Outcome                                           | Secondary Outcome                                                                 | Dose                     | Length of Treatment | Results                                      |
|--------------------------------|----------------|------------|-----------------------------------|------|-------------|--------------------------------------|-----------------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------|-------------------------|------------------|---------------------------------------------|
| Annamaria Staiano et al. [32]  | 2000           | Italy      | Randomized, double-blind parallel trial | 57   | 5.7 ± 4.2   | Glucomannan vs. placebo              | Soluble                     | Reduction of laxative or suppository use                   | Colonic transit time                                                | 100 mg/kg, twice daily | 12 weeks         | Stool frequency: p < 0.01 Reduction of laxative or suppository use: p < 0.01 Colonic transit time: p = 0.05 |
| Vera Loening-Baucke et al. [33]| 2004           | USA        | Randomized, double-blind crossover trial | 31   | 4.5–11.7    | Glucomannan vs. placebo              | Soluble                     | Successful treatment: ≥3 BMs per week and ≤1 soiling episode in the last 3 weeks with no abdominal pain | None listed                  | 100 mg/kg, body weight daily Maximum dose: 5 g daily | 4 weeks                   | Successful treatment: p = 0.05 Colonic transit time: p = 0.015 |
| Gemma Castillejo et al. [34]   | 2006           | Spain      | Randomized, double-blind parallel trial | 56   | 3–10        | Cocoa husk vs. placebo               | Insoluble                   | Colonic transit time                                      | None listed                  | 3–6 years: 8 g daily 7–10 years: 16 g daily 12–16 years: 25 g daily | 4 weeks                   |                      |
| Freddy T.M. Kokke et al. [35]  | 2008           | The Netherlands | Randomized, double-blind parallel trial | 97   | 1–13        | Partially hydrolyzed guar gum vs. lactulose | Soluble                     | Fecal incontinence                                       | Stool frequency: p = 0.481 Abdominal pain: p = 0.084 Flatulence: p = 0.79 | &lt;15 kg: 10 g daily 15-20 kg: 20 g daily &gt;20 kg: 30 g daily | 8 weeks                   |                      |
| Gonca Ustundag et al. [31]     | 2010           | Turkey     | Randomized, prospective parallel trial | 61   | 4–16        | Partially hydrolyzed guar gum vs. lactulose | Soluble                     | Stool frequency: p = 0.05                               | Stool consistency: p = 0.16 Stool frequency: p = 0.05 Abdominal pain: p = 0.05 | 4–6 years: 3 g daily 6–12 years: 4 g daily 12–16 years: 5 g daily | 4 weeks                   | Stool frequency: p = 0.05 Stool consistency: p = 0.15 Abdominal pain: p = 0.05 |
| Anna Chmielewska et al. [36]   | 2011           | Poland     | Randomized, double-blind parallel trial | 72   | 3–16        | Glucomannan vs. placebo              | Soluble                     | Treatment success: ≥3 stools per week with no soiling   | Stool consistency: p = 0.99 Stool frequency: p = 0.58 | 2.52 g daily               | 4 weeks                   | Treatment success: p = 0.99 Stool consistency: p = 0.58 Stool frequency: p = 0.11 Colonic transit time: p = 0.42 Flatulence: p = 0.78 Abdominal pain: p = 0.0001 |
| Paolo Quistadomo et al. [37]   | 2012           | Italy      | Randomized, prospective, open label, parallel trial | 100  | 4–10        | Acacia fiber + Psyllium fiber + Fructose vs. polyethylene glycol 3350 with electrolytes | Soluble (acacia fiber, psyllium fiber) | Stool frequency: p = 0.621                               | Improvement of gastrointestinal symptoms: p = 0.751 Fecal incontinence: p = 0.621 | 16.8 g daily               | 8 weeks                   | Stool frequency: p = 0.621 Stool consistency: p = 0.751 Fecal incontinence: p = 0.621 |
| Author          | Year Published | Location | Type of Study                      | N       | Age (Years) | Fiber Type                          | Water Soluble or Insoluble   | Primary Outcome                                           | Secondary Outcome                                      | Dose                | Length of Treatment | Results                                                                 |
|-----------------|----------------|----------|------------------------------------|---------|-------------|-------------------------------------|-------------------------------|----------------------------------------------------------|-------------------------------------------------------|------------------|------------------|-------------------------------------------------------------------------|
| Thabata K. Weber et al. [38] | 2014           | Brazil   | Randomized, double-blind parallel trial | 54      | 4–12        | Fructooligosaccharides, inulin, gum arabic, resistant starch, soy polysaccharide, cellulose vs. placebo | Soluble (fructooligosaccharides, inulin) Insoluble (cellulose) | Therapeutic failure (oral stool softeners or enemas was required during the trial) | Stool frequency Steal consistency | <18 kg: 7.6 g daily<br>18 kg: 13.2 g daily | 4 weeks<br>Therapeutic failure: p = 0.933<br>Stool frequency: p = 0.014 Steal Consistency p = 0.003 |
| Célia A.V. Beleli et al. [39] | 2015           | Brazil   | Randomized, double-blind crossover trial | 20      | 4–16        | Galactooligosaccharides vs. placebo | Soluble                          | Stool frequency                                            | Staining Steal consistency None listed | 1.7 g daily | 30 days          | Stool frequency: p < 0.0001<br>Staining: p < 0.0001 Steal consistency: p = 0.0014 |
| Ricardo Closa-Monasterolo et al. [40] | 2017           | Spain    | Randomized, double-blind parallel trial | 17      | 2–5         | Inulin-type fructans vs. placebo | Soluble                          | Stool consistency                                          | Stool frequency gastrointestinal symptoms | 4 g daily | 6 weeks           | Stool consistency: p = 0.040<br>Stool frequency: p = 0.328 Gastrointestinal symptoms (pain): p = 0.014 |
A second investigation found similar results. Romano et al. studied PHGG supplementation in patients with both chronic abdominal pain and IBS [26]. In a randomized, double-blind pilot study, sixty children received either PHGG or placebo for four weeks to determine a change in severity of abdominal pain and IBS. Children in the treatment group were provided 5 g/day of PHGG, mixed in fruit-juice, whereas the placebo group received only fruit-juice. Three validated questionnaires were used to measure clinical symptoms, which were the “Birmingham IBS Symptom Questionnaire”, “Wong Baker Faces Pain Rating Score”, and the “Bristol Stool Scale”. The group treated with PHGG reported greater normalization of bowel movements, reduction in clinical symptoms of IBS and intensity of abdominal pain, compared to the control group (Table 1).

3.1.3. Glucomannan

Glucomannan is a nonabsorbable fiber from the Japanese Konjac plant [41]. It has traditionally been consumed in jelly, noodles, jams, as well as other food products and in Chinese medicine [41]. Clinical studies in healthy adults have demonstrated that Glucomannan improves the colon’s health by increasing stool bulk and stool frequency, without causing gastrointestinal side effects [42]. Three studies evaluated the effect glucomannan supplementation on childhood constipation [32,33,36].

Staiano et al. evaluated the effects of glucomannan on FC in neurologically impaired children [32]. In a double-blind placebo-controlled clinical trial, twenty children with brain damage and chronic constipation received either glucomannan or placebo for twelve weeks to assess the effect of glucomannan, in colonic transit and stool frequency (primary outcomes). Glucomannan was administered at 100 mg/kg twice daily. Bowel movements, consistency, and presence of abdominal pain were recorded daily, via a diary card. Nineteen participants completed the treatment phase. The authors found that treatment with glucomannan significantly increased stool frequency and decreased consistency and painful defecation, but there were no significant effects on colonic transit (Table 2).

Loening-Baucke et al. found that glucomannan improves stool frequency [33]. In a double-blind, randomized, crossover study, thirty-one children received either fiber or placebo for four weeks. Glucomannan was dosed at 100 mg/kg of body weight, daily, with a maximum dose of 5 g per day. Abdominal pain and stools were tracked using a diary that evaluated daily bowel movements and episodes of fecal incontinence and pain. Glucomannan treatment was considered successful if children experienced greater or equal to three bowel movements per week and less than one fecal incontinence episode, in the previous three weeks. The authors found that more children experienced a significantly more success with the fiber treatment than with placebo (Table 2).

Chmielewska’s findings contradict the results of the previous two studies [36]. In a double-blind, randomized placebo-controlled trial, eighty children received either glucomannan or placebo for four weeks. Treatment was successful if there were ≥3 stools per week and no episodes of fecal incontinence. Glucomannan was dosed at 2.52 g per day. Bowel diaries were used to document stool patterns. Seventy-two participants completed the study, with twenty children in the glucomannan group experiencing success, compared to twenty-one children in the placebo group. Thus, the study did not find a significant difference in therapeutic success between glucomannan and placebo, for FC in children (Table 2).

3.1.4. Inulin

Inulin is a polysaccharide commonly found in roots, tubers, and plant rhizomes from common foods, including asparagus, chicory, garlic, onion, and artichoke [43]. A 2014 meta-analysis [44] of randomized controlled clinical trials involving two hundred and fifty-two subjects (four adult studies and one pediatric study that was included in this review) found that inulin improved stool frequency, stool consistency, and transit time. Since the publication of the meta-analysis, one more study has evaluated the effect of inulin on children with constipation [40].

In 2017, Closa-Monasterolo et al. assessed the effects of inulin-type fructans in children with FC [40]. In a double-blind, randomized, placebo-controlled parallel group trial, twenty-two children...
received either two doses of inulin-type fructans or placebo for six weeks to determine its effect in stool consistency and frequency. The inulin-type fructans were provided at 4 g daily. Seventeen children completed the study. It was found that children who received the inulin-type fructans had decreased stool consistency, according to the modified Bristol Scale (Table 2).

3.1.5. Oligosaccharides

Oligosaccharides are a non-digestible complex carbohydrate source [45] that increases fecal weight and water in the stools [46]. Galactooligosaccharides (FOS) exemplify this type of soluble dietary fiber [39]. One study evaluated the effect of oligosaccharides on stool consistency in the pediatric population [39].

Beleli et al. assessed the effects of galactooligosaccharides (GOS) on constipated patients and found that it improved the GI symptoms [39]. In a double-blinded, placebo-controlled, crossover trial, twenty patients received either GOS or placebo for thirty days to evaluate changes in constipation signs and symptoms. A fifteen-day washout period separated the trial, followed by another thirty days on the alternative intervention. GOS were consumed at 1.7 g, daily, and home visits occurred, biweekly, to collect data and measure compliance and symptoms. GOS ingestion resulted in significant improvements, compared to placebo, including bowel movement frequency, relief of straining during defecation, and a decrease in stool consistency. No side effects were noted (Table 2).

3.1.6. Cocoa husk

The outer shell of cocoa beans that encase the nibs are rich in soluble fiber [47]. One study evaluated the effect of Cocoa husk supplementation on childhood FC.

Castillejo et al. found that supplementation with cocoa husk improved the intestinal transit time, as well as reduced the percentage of patients who reported hard stools [34]. In a parallel, randomized, double-blind, controlled trial, fifty-six children received either a cocoa husk supplement or placebo for four weeks, in addition to the toilet regimen. Total colonic transit time was the primary outcome of treatment success. The patient’s parents assessed the bowel movement and stool consistency, via a diary. Forty-eight children completed the study, with a significant decrease in the intestinal transit time, in the cocoa husk group, from 45.4 ± 38.4 h, versus 8.7 ± 28.9 h, in the placebo group. There was a significant difference in stool consistency in favor of cocoa husk. The cocoa husk group also noted an improvement in the frequency of bowel movements but the difference was non-significant. There were no side effects reported during the study (Table 2).

3.1.7. Psyllium fiber

Psyllium is a common over the counter fiber supplement. Psyllium is derived from the seeds of the plant genus Plantago, and acts as soluble viscous fiber [48]. Due to its ability to hold water, it is sometimes used to treat both constipation and mild diarrhea. One randomized control study evaluated psyllium in children with constipation [25].

Shulman et al. found that the psyllium fiber lessened the frequency of abdominal pain in children with IBS [25]. In a randomized, double-blind trial, eighty-four children received either psyllium or placebo for six weeks. Children 7–11 years of age, received 6 g of psyllium per day, while those of age 12–18 years, received 12 g. Participants recorded the daily abdominal pain severity and pain frequency. Interestingly, those treated with psyllium experienced a significant reduction of pain episodes but not pain intensity (Table 1).

3.2. Studies on Combined Fiber Types

Transgalacto-oligosaccharides, inulin, soy fiber, resistant starch, acacia fiber, and psyllium fiber

It has been speculated that a combination of different fiber types, including short and long chain fibers may be a more effective approach for controlling constipation, due to its action on different parts
of the colon. Three studies evaluated the effects of a combination of fiber blends, in children with constipation [35,37,38].

A study hypothesized that a combination of fibers would have a more beneficial effect, compared to lactulose, which acts mainly in the proximal colon. However, the hypothesis was unproven. Kokke et al. [35] did not find a fiber mixture to be a more effective for the treatment of childhood constipation. In a randomized, double-blind, prospective controlled study, one hundred and thirty-five participants received either a yogurt drink with mixed dietary fibers or lactulose for 8 weeks. Children were then weaned for 4 weeks. The fiber mixture contained 3.0 g transgalacto-oligosaccharides, 3.0 g inulin, 1.6 g soy fiber, and 0.33 g resistant starch, per 100 mL. Parents, or the patient, recorded the defecation frequency, consistency of stool, abdominal pain, flatulence, and episodes of fecal incontinence, in a bowel diary. Ninety-seven children completed the investigation (28% drop out rate). The authors did not find a difference in defecation frequency or fecal incontinence between both groups. Those treated with lactulose noted softer stools. Thus, lactulose and a dietary fiber mixture were found to be equally effective for the treatment of childhood constipation (Table 2).

Data suggests gel-forming fibers soften hard stools in constipation; although fermented in different areas of the bowel, Acacia fiber and psyllium are two examples of the gel-forming fibers [49]. One randomized control study evaluated the effects of these fiber blends in children with constipation [37]. Quitadamo et al. studied a fiber mixture, acacia fiber, psyllium fiber, and fructose, and found that the fiber mixture improved constipation comparable to polyethylene glycol (PEG) [37]. In a randomized, open-label, prospective, controlled, parallel-group study, hundred children received either the fiber mixture or PEG, for eight weeks, to determine effects on the gastrointestinal symptoms. For eight weeks, children were provided with 16.8 g of the fiber mixture. Gastrointestinal symptoms were recorded via stool diary. The frequency of bowel movements and stool consistency were improved in both groups, although PEG was deemed more palatable (Table 2).

Weber et al. evaluated a fiber mix in the treatment of chronic constipation in children [38]. In a placebo-controlled, double-blind study, fifty-seven children received either a fiber mixture of several prebiotic sources, including FOS, inulin, gum acacia, resistant starch, soy polysaccharides, and cellulose, or placebo for four weeks. Dosing was based on the child’s body weight. Children under 18 kg received 3.8 g of fiber, twice daily, and was compared to children >18 kg that received 7.6 g of fiber twice daily. Participants completed the daily stool questionnaires. Patients in the fiber group significantly increased the frequency of bowel movements, as well as improved their stool consistency (Table 2).

3.3. Children’s Acceptance of Fiber

As important as fiber supplementation, is its acceptability by children. Two studies investigated whether children are amenable to increase their dietary fiber intake. Brauchla et al. [50] studied the effect of introducing two high fiber snacks per day. In a randomized controlled prospective intervention study, children between 7 and 11 years were given either two high fiber snacks per day, or their usual snacks for eight weeks. Twenty-four-hour dietary recalls were used to assess intake and acceptability. It was found that children who were offered the high fiber snacks increased their fiber intake by 2.5 g per day. Making high fiber foods and snacks more consistently available to children is suggested as a means of increasing fiber intake.

Long-term adherence to a high fiber diet can also be improved with a team approach, including a physician and registered dietitian. Karagiozoglou-Lampoudi et al. [51] studied the compliance to a high fiber/high water regime in children with a refractory FC. In a prospective randomized study, forty-two children followed their physician’s dietary advice for the management of constipation, while forty-four children received dietary management by a registered dietitian. Children seen by a dietitian increased their fiber and water intake more than those who were not. Personalized dietary modification by a nutrition professional is recommended to optimize children’s compliance to high fiber/high water diet.
4. Discussion

Children consume a suboptimal amount of dietary fiber, due to limited intake of vegetables, fruits, and whole grains [52]. In 2008, the Feeding Infants and Toddlers Study (FITS) assessed the usual nutrient intakes of three thousand two hundred and seventy-three infants, toddlers, and preschoolers. Through a random sample of US children, it was determined that most toddlers and preschoolers consume a low-intake of dietary fiber [52]. Anecdotal evidence suggests that children who do not consume enough fiber experience more constipation, but the role of supplemental fiber in treating FC remains controversial [53].

Fibers are also known to influence microbiota composition. The gut contains over a 100 trillion microbial cells, which have an impact on physiology, metabolism, and nutrition [54]. Inadequate fiber intake in the long-term may contribute to a gut dysfunction by reducing these important microbial taxa. Increasing fiber intake slowly, over time, is suggested as it will allow the microbiota to adapt to higher doses [54].

Still, the NASPGHAN/ESPGHAN guidelines published in 2014 [10] stated that there was no evidence to support the use of fiber in the treatment of FC in children, and therefore recommend giving children a “normal” amount of fiber for the child’s age. The Rome IV criteria, published in 2016 [1], does not mention the use of fiber among the recommended treatments for IBS in children. Since then, three pediatric randomized clinical trials have been published, two of them on the treatment of FC and one on IBS. Although all of them showed positive results, we found great variability among the studies we reviewed. Thus, despite most of them having positive results, we believe that previous recommendations continue to be valid.

Our review included ten randomized clinical trials on the efficacy of fiber, for the treatment of FC. The studies differed in methods, fiber types, doses, endpoints, and age groups. Among these studies, some had a placebo arm as comparator and others compared fiber against other treatments. The variability among studies in combination with the small size of some of them does not allow combining the data for a meta-analysis.

There are at least twenty-six different types of fibers. Out of all types of fiber, only nine types have been studied for the treatment of FC and IBS in children (guar gum, glucomannan, cocoa husk, psyllium, inulin, corn fiber, acacia fiber, oligosaccharides, and soy fiber). One of the fibers most commonly studied is glucomannan. Two, out of three small studies, [32,33,36] concluded that its use was beneficial for the treatment of FC.

In one of these studies, children received glucomannan, in combination with a standard laxative treatment, while another trial was conducted in children with FC and the altered neurological status. Both studies showed significant benefits. A third study [36] did not find glucomannan to be effective; however, the dose of glucomannan used in this study was low. Although the results of the trials of glucomannan could be considered encouraging, more studies should be conducted before recommending its use in clinical practice.

Two studies [31,35] examined the use of dietary fiber versus lactulose, in the treatment of FC, using a different design. Both studies concluded that they were equally effective. None of the studies included a placebo arm. The design of Ustundag’s study made it prone to bias. Only the subjects treated with PHGG were recommended to increase their fluid intake, while children in the placebo group were not. Although there is no evidence that fluid is beneficial for the treatment of FC, we cannot rule out that the design of the study influenced the outcome. The dropout rate in Kokke’s study was unusually high.

Differentiating between the IBS-C and FC is sometimes challenging [55]. Forty-five percent of children with FC report abdominal pain [55] and it is sometimes unclear if some of them, in fact, may have IBS-C. Poorly absorbed oligosaccharides are FODMAPs that can trigger IBS symptoms. Interestingly, three studies assessed the effect of FODMAP fibers for the treatment of FC. Closa-Monasterolo and Kokke found that inulin supplementation improved stool consistency, in children with FC. These results parallel the findings with other oligosaccharides as well [39].
Chumpitazi et al. [56] found that fructans exacerbate the IBS symptoms in children. None of the studies [35,39,40] reported any side effects resulting from the use of FODMAPs, for the treatment of FC. This may indicate that the diagnosis of FC can be well differentiated at the time of the inclusion criteria or that the lower dose of FODMAPs used in these studies was not enough to trigger the detrimental symptoms.

Only three randomized clinical trials with a total of a hundred and ninety-six children were published in English, in the last thirty-three years, for the treatment of IBS. All of them used a placebo arm and showed positive results, although the study design and type of fiber differed. Romano et al. studied the effect of PHGG in children with IBS and chronic abdominal pain. Shulman et al. studied the effect of psyllium in IBS and Feldman studied the effect of corn diet in children with RAP. The differences in inclusion criteria, design, and endpoints did not allow us to arrive at a firm conclusion on the effect of fiber, in children with IBS.

One objective of the 2010 Dietary Guidelines [57] was to increase the dietary fiber (DF) intake. None of the studies investigated the effects of increasing fiber from whole foods rich in fiber that could be a more “natural” way of increasing the fiber intake. Fiber from whole foods may yield different results than that of supplemental fiber therapy. Thus, studies that evaluate the impact of increasing fiber, from whole foods, in children with FC and IBS, should be encouraged.

To improve adherence and therapeutic success, recommendations for treatment need to be simple and easy to understand. Three studies [35,37,38] utilized a combination of multiple fiber types in their treatment, which may be difficult to replicate naturally, in daily practice. Although the studies found their treatments to be comparable to PEG and lactulose, it is well established that parents’ adherence to physician recommendations is low [18], and advising multiple fiber types may be impracticable.

There are limitations to this review. Our review only included studies in English. Some positive trials in other languages may have not been considered. We cannot exclude that our review would have arrived at a different conclusion if studies in other languages had been included. One of the studies used fiber in low doses [36]. It is unknown whether fiber used at a larger dose could have resulted in better outcomes. However, the use of high doses of fiber may not always be beneficial. Bulkier stools may be uncomfortable for some children and a diet rich of some types of fibers (FODMAPs) may be detrimental.

5. Conclusions

Most studies on the use of fiber for the treatment of FC and IBS have shown its benefit. However, due to differences in design, such as the use of multiple types of fibers, dosing and length of treatment and small sample sizes and risk of bias, we are unable to make a definitive recommendation supporting the use of fiber for the treatment of FC and IBS. The conclusions of our review are, thus, in agreement with NASPGHAN/ESPGHAN recommendations that a normal fiber intake should be encouraged in children with and without FC. The small number of clinical trials on the use of fiber in children with IBS do not allow for arriving at a definitive conclusion. Practitioners should be cautious at the time of selecting the type and dose of fibers in children with IBS to avoid worsening symptoms.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Benninga, M.A.; Faure, C.; Hyman, P.E.; St James Roberts, I.; Schechter, N.L.; Nurko, S. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. *Gastroenterology* 2016. [CrossRef] [PubMed]
2. Jarrett, M.; Heitkemper, M.; Czyzewski, D.I.; Shulman, R. Recurrent abdominal pain in children: Forerunner to adult irritable bowel syndrome? *J. Spec. Pediatr. Nurs.* 2003, 8, 81–89. [CrossRef] [PubMed]
3. Devanarayana, M.N.; Rajindrajith, S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. *World J. Gastroenterol.* 2018, 24, 2211–2235. [CrossRef] [PubMed]
4. Koppen, I.J.; Vriesman, M.H.; Saps, M.; Rajindrajith, S.; Shi, X.; van Etten-Jamaludin, F.S.; Di Lorenzo, C.; Benninga, M.A.; Tabbers, M.M. Prevalence of Functional Defecation Disorders in Children: A Systematic Review and Meta-Analysis. *J. Pediatr.* 2018, 198, 121–130.e6. [CrossRef] [PubMed]

5. Varni, J.W.; Lane, M.M.; Burwinkle, T.M.; Fontaine, E.N.; Youssef, N.N.; Schwimmer, J.B.; Pardee, P.E.; Pohl, J.F.; Easley, D.J. Health-related quality of life in pediatric patients with irritable bowel syndrome: A comparative analysis. *J. Dev. Behav. Pediatr.* 2006, 27, 451–458. [CrossRef] [PubMed]

6. Youssef, N.N.; di Lorenzo, C. Childhood constipation: Evaluation and treatment. *J. Clin. Gastroenterol.* 2001, 33, 199–205. [CrossRef] [PubMed]

7. Leiper, J.B. Intestinal water absorption–implications for the formulation of rehydration solutions. *Int. J. Sports Med.* 1998, 19 (Suppl. 2), S129–S132. [CrossRef] [PubMed]

8. Rose, C.; Parker, A.; Jefferson, B.; Cartmell, E. The Characterization of Feces and Urine: A Review of the Literature to Inform Advanced Treatment Technology. *Crit. Rev. Environ. Sci. Technol.* 2015, 45, 1827–1879. [CrossRef] [PubMed]

9. Arnaud, M.J. Mild dehydration: A risk factor of constipation? *Eur. J. Clin. Nutr.* 2003, 57 (Suppl. 2), S88–S895. [CrossRef] [PubMed]

10. Tabbers, M.M.; Di Lorenzo, C.; Berger, Y.M.; Faure, C.; Langendam, W.M.; Nurko, S.; Staiano, A.; Vandenplas, Y.; Benninga, A.M. Evaluation and treatment of functional constipation in infants and children: Evidence-based recommendations from ESPGHAN and NASPGHAN. *J. Pediatr. Gastroenterol. Nutr.* 2014, 58, 258–274. [CrossRef] [PubMed]

11. Yang, C.H.; Punati, J. Practice patterns of pediatricians and trainees for the management of functional constipation compared with 2006 NASPGHAN guidelines. *J. Pediatr. Gastroenterol. Nutr.* 2015, 60, 308–311. [CrossRef] [PubMed]

12. Koppen, I.J.N.; Vriesman, M.H.; Tabbers, M.M.; Di Lorenzo, C.; Benninga, M.A. Awareness and Implementation of the 2014 ESPGHAN/NASPGHAN Guideline for Childhood Functional Constipation. *J. Pediatr. Gastroenterol. Nutr.* 2018, 66, 732–737. [CrossRef] [PubMed]

13. Heizer, W.D.; Southern, S.; McGovern, S. The role of diet in symptoms of irritable bowel syndrome in adults: A narrative review. *J. Am. Diet. Assoc.* 2009, 109, 1204–1214. [CrossRef] [PubMed]

14. Food and Drug Administration. Science Review of Isolated and Synthetic Non-Digestible Carbohydrates, November 2016. Available online: https://www.fda.gov/downloads/Food/LabelingNutrition/UCM529049.pdf (accessed on 1 October 2018).

15. Bongers, M.E.; Benninga, M.A.; Maurice-Stam, H.; Grootenhuis, M.A. Health-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthood. *Health Qual. Life Outcomes* 2009, 7, 20. [CrossRef] [PubMed]

16. Tabbers, M.M.; Benninga, M.A. Constipation in children: Fibre and probiotics. *BMJ Clin. Evid.* 2015.

17. Steiner, S.A.; Torres, M.R.; Penna, F.J.; Gazzinelli, B.F.; Corradi, C.G.; Costa, A.S.; Ribeiro, I.G.; de Andrade, E.G.; de Melo, M.D.C.B. Chronic functional constipation in children: Adherence and factors associated with drug treatment. *J. Pediatr. Gastroenterol. Nutr.* 2014, 58, 598–602. [CrossRef] [PubMed]

18. Koppen, I.J.N.; van Wassenaer, E.A.; Barendsen, R.W.; Brand, P.L.; Benninga, M.A. Adherence to Polyethylene Glycol Treatment in Children with Functional Constipation Is Associated with Parental Illness Perceptions, Satisfaction with Treatment, and Perceived Treatment Convenience. *J. Pediatr.* 2018, 199, 132–139.e1. [CrossRef] [PubMed]

19. Gordon, M.; MacDonald, J.K.; Parker, C.E.; Akobeng, A.K.; Thomas, A.G. Osmotic and stimulant laxatives for the management of childhood constipation. *Cochrane Database Syst. Rev.* 2016, 17. [CrossRef] [PubMed]

20. Singh, M. Communication as a Bridge to Build a Sound Doctor-Patient/Parent Relationship. *Indian J. Pediatr.* 2016, 83, 33–37. [CrossRef] [PubMed]

21. Akin, D.E.; Rigsby, L.L. Corn fiber: Structure, composition, and response to enzymes for fermentable sugars and coproducts. *Appl. Biochem. Biotechnol.* 2008, 144, 59–68. [CrossRef] [PubMed]

22. Konings, E.; Schoffelen, P.F.; Stegen, J.; Blaa, E.E. Effect of polydextrose and soluble maize fibre on energy metabolism, metabolic profile and appetite control in overweight men and women. *Br. J. Nutr.* 2014, 111, 111–121. [CrossRef] [PubMed]

23. Timm, D.A.; Thomas, W.; Boileau, T.W.; Williamson-Hughes, P.S.; Slavin, J.L. Polydextrose and soluble corn fiber increase five-day fecal wet weight in healthy men and women. *J. Nutr.* 2013, 143, 473–478. [CrossRef] [PubMed]
24. Feldman, W.; McGrath, P.; Hodgson, C.; Ritter, H.; Shipman, R.T. The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent, abdominal pain. Results in a prospective, double-blind, randomized, controlled trial. *Am. J. Diseases Child.* 1985, 139, 1216–1218. [CrossRef]  
25. Shulman, R.J.; Hollister, E.B.; Cain, K.; Czyzewski, D.I.; Self, M.M.; Weidler, E.M.; Devaraj, S.; Luna, R.A.; Versalovic, J.; Heitkemper, M. Psyllium Fiber Reduces Abdominal Pain in Children with Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. *Clin. Gastroenterol. Hepatol.* 2017, 15, 712–719.e4. [CrossRef] [PubMed]  
26. Romano, C.; Comito, D.; Famiani, A.; Calamara, S.; Loddo, I. Partially hydrolyzed guar gum in pediatric functional abdominal pain. *World J. Gastroenterol.* 2013, 19, 235–240. [CrossRef] [PubMed]  
27. Sharma, G.; Sharma, S.; Kumar, A.; Al-Muhtaseb, A.H.; Naushad, M.; Ghfar, A.A.; Mola, G.T.; Stadler, F.J. Guar gum and its composites as potential materials for diverse applications: A review. *Carbohydr. Polym.* 2018, 199, 534–545. [CrossRef] [PubMed]  
28. Yoon, S.J.; Chu, D.C.; Raj Juneja, L. Chemical and physical properties, safety and application of partially hydrolyzed guar gum as dietary fiber. *J. Clin. Biochem. Nutr.* 2008, 42, 1–7. [CrossRef] [PubMed]  
29. Polymeros, D.; Beintaris, I.; Gaglia, A.; Karamanolis, G.; Papanikolaou, I.S.; Dimitriadis, G.; Triantafyllou, K. Partially hydrolyzed guar gum accelerates colonic transit time and improves symptoms in adults with chronic constipation. *Dig. Dis. Sci.* 2014, 59, 2207–2214. [CrossRef] [PubMed]  
30. Belo, G.M.; Diniz Ada, S.; Pereira, A.P. Effect of partially hidrolized guar-gum in the treatment of functional constipation among hospitalized patients. *Arq. Gastroenterol.* 2008, 45, 93–95. [CrossRef]  
31. Ustundag, G.; Kuloglu, Z.; Kirbas, N.; Kansu, A. Can partially hydrolyzed guar gum be an alternative to lactulose in treatment of childhood constipation? *Turk. J. Gastroenterol.* 2010, 21, 360–364. [CrossRef] [PubMed]  
32. Staiano, A.; Simeone, D.; Del Giudice, E.; Miele, E.; Tozzi, A.; Toraldo, C. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. *J. Pediatr.* 2000, 136, 41–45. [CrossRef]  
33. Loening-Bauke, V.; Miele, E.; Staiano, A. Fiber (glucomannan) is beneficial in the treatment of childhood constipation. *Pediatrics* 2004, 113, e259–e264. [CrossRef] [PubMed]  
34. Castillejo, G.; Bullo, M.; Anguera, A.; Escribano, J.; Salas-Salvado, J. A controlled, randomized, double-blind trial to evaluate the effect of a supplement of cocoa husk that is rich in dietary fiber on colonic transit in constipated pediatric patients. *Pediatrics* 2006, 118, e641–e648. [CrossRef] [PubMed]  
35. Kokke, F.T.; Scholten, P.A.; Alles, M.S.; Decates, T.S.; Fiselier, T.J.; Tolboom, J.J.; Kimpen, J.L.; Benninga, M.A. A dietary fiber mixture versus lactulose in the treatment of childhood constipation: A double-blind randomized controlled trial. *J. Pediatr. Gastroenterol. Nutr.* 2008, 47, 592–597. [CrossRef] [PubMed]  
36. Chmielewksa, A.; Horvath, A.; Dziechcizarz, P.; Szajejewska, H. Glucomannan is not effective for the treatment of functional constipation in children: A double-blind, placebo-controlled, randomized trial. *Clin. Nutr.* 2011, 30, 462–468. [CrossRef] [PubMed]  
37. Quitadamo, P.; Coccorullo, P.; Giannetti, E.; Romano, C.; Chiaro, A.; Campanozzi, A.; Poli, E.; Cucchiara, S.; Di Nardo, G.; Staiano, A. A randomized, prospective, comparison study of a mixture of acacia fiber, psyllium fiber, and fructose vs. polyethylene glycol 3350 with electrolytes for the treatment of chronic functional constipation in childhood. *J. Pediatr.* 2012, 161, 710–715.e1. [CrossRef]  
38. Weber, T.K.; Toporovski, M.S.; Tahak, S.; Neufeld, C.B.; de Morais, M.B. Dietary fiber mixture in pediatric patients with controlled chronic constipation. *J. Pediatr. Gastroenterol. Nutr.* 2014, 58, 297–302. [CrossRef] [PubMed]  
39. Beleli, C.A.; Antonio, M.A.; dos Santos, R.; Pastore, G.M.; Lomazi, E.A. Effect of 4’galactooligosaccharide on constipation symptoms. *J. Pediatr.* 2015, 91, 567–573. [CrossRef] [PubMed]  
40. Closa-Monasterolo, R.; Ferre, N.; Castillejo-De Villasante, G.; Luque, V.; Gispert-Llaurado, M.; Zaragoza-Jordana, M.; Theis, S.; Escribano, J. The use of inulin-type fructans improves stool consistency in constipated children. A randomized clinical trial: Pilot study. *Int. J. Food Sci. Nutr.* 2017, 68, 587–594. [CrossRef] [PubMed]  
41. Yang, D.; Yuan, Y.; Wang, L.; Wang, X.; Mu, R.; Pang, J.; Xiao, J.; Zheng, Y. A Review on Konjac Glucomannan Gels: Microstructure and Application. *Int. J. Mol. Sci.* 2017, 18, 2250. [CrossRef] [PubMed]  
42. Chen, H.L.; Cheng, H.C.; Liu, Y.J.; Liu, S.Y.; Wu, W.T. Konjac acts as a natural laxative by increasing stool bulk and improving colonic ecology in healthy adults. *Nutrition* 2006, 22, 1112–1119. [CrossRef] [PubMed]
43. Hughes, S.R.; Qureshi, N.; Lopez-Nunez, J.C.; Jones, M.A.; Jarodsky, J.M.; Galindo-Leva, L.A.; Lindquist, M.R. Utilization of inulin-containing waste in industrial fermentations to produce biofuels and bio-based chemicals. *World J. Microbiol. Biotechnol.* **2017**, *33*, 78. [CrossRef] [PubMed]

44. Collado Yurrita, L.; San Mauro Martin, I.; Ciudad-Cabanas, M.J.; Calle-Puron, M.E.; Hernandez Cabria, M. Effectiveness of inulin intake on indicators of chronic constipation; a meta-analysis of controlled randomized clinical trials. *Nutr. Hosp.* **2014**, *30*, 244–252. [PubMed]

45. Roberfroid, M.B. Health benefits of non-digestible oligosaccharides. *Adv. Exp. Med. Biol.* **1997**, *427*, 211–219. [PubMed]

46. Sabater-Molina, M.; Larque, E.; Torrella, F.; Zamora, S. Dietary fructooligosaccharides and potential benefits on health. *J. Physiol. Biochem.* **2009**, *65*, 315–328. [CrossRef] [PubMed]

47. Benera, M.A. Zeitschrift fur Lebensmitteluntersuchung und -Forschung A; Springer: Berlin, Germany, 1998; Volume 207, pp. 105–109.

48. Christodoulides, S.; Dimidi, E.; Fragkos, K.C.; Farmer, A.D.; Whelan, K.; Scott, S.M. Systematic review with meta-analysis: Effect of fibre supplementation on chronic idiopathic constipation in adults. *Aliment. Pharmacol. Therapeut.* **2016**, *44*, 103–116. [CrossRef] [PubMed]

49. McKorie, J.W., Jr. Evidence-Based Approach to Fiber Supplements and Clinically Meaningful Health Benefits, Part 2: What to Look for and How to Recommend an Effective Fiber Therapy. *Nutr. Today* **2015**, *50*, 90–97. [CrossRef] [PubMed]

50. Brauchla, M.; McCabe, G.P.; Miller, K.B.; Kranz, S. The effect of high fiber snacks on digestive function and diet quality in a sample of school-age children. *Nutr. J.* **2013**, *12*, 153. [CrossRef] [PubMed]

51. Karagiozoglou-Lampoudi, T.; Daskalou, E.; Agakidis, C.; Savvidou, A.; Apostolou, A.; Vlahavas, G. Personalized diet management can optimize compliance to a high-fiber, high-water diet in children with refractory functional constipation. *J. Acad. Nutr. Diet.* **2012**, *112*, 725–729. [CrossRef] [PubMed]

52. Butte, N.F.; Fox, M.K.; Briefel, R.R.; Siega-Riz, A.M.; Dwyer, J.T.; Deming, D.M.; Reidy, K.C. Nutrient intakes of US infants, toddlers, and preschoolers meet or exceed dietary reference intakes. *J. Am. Diet. Assoc.* **2010**, *110* (Suppl. 12), S27–S37. [CrossRef] [PubMed]

53. Piccoli de Mello, P.; Eifer, D.A.; Daniel de Mello, E. Use of fibers in childhood constipation treatment: Systematic review with meta-analysis. *J. Pediatr.* **2018**. [CrossRef] [PubMed]

54. Makki, K.; Deehan, E.C.; Walter, J.; Bäckhed, F. The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease. *Cell Host Microbe* **2018**, *23*, 705–715. [CrossRef] [PubMed]

55. Cremonini, F.; Lembo, A. IBS with constipation, functional constipation, painful and non-painful constipation: E Pluribus...Plures? *Am. J. Gastroenterol.* **2014**, *109*, 885–886. [CrossRef] [PubMed]

56. Chumpitazi, B.P.; McMeans, A.R.; Vaughan, A.; Ali, A.; Orlando, S.; Elsaadi, A.; Shulman, R.J. Fructans Exacerbate Symptoms in a Subset of Children with Irritable Bowel Syndrome. *Clin. Gastroenterol. Hepatol.* **2018**, *16*, 219–225.e1. [CrossRef] [PubMed]

57. Polon, R.; Stookey, E. *Dietary Guidelines for Americans*, 2010, 2nd ed.; Lifestyle Medicine: Boca Raton, FL, USA, 2013; pp. 131–147.

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).